Introduction {#s1}
============

Myotonia congenita is a genetic disease characterized by impaired muscle relaxation after forceful contraction (myotonia). The term "myotonia" indicates the main characteristic of this pathology, i.e., the presence of the so-called *myotonic phenomenon*, usually defined as "the delay in muscle relaxation after a prolonged contraction" ([@B1], [@B2]). The diseases characterized by the presence of the "myotonia" can be subdivided into two large groups ([@B3]): Myotonic Dystrophies (DM), characterized by the *presence* of progressive muscular atrophy and weakness, and multi-systemic involvement and Non-dystrophic myotonias (NDM), characterized by the *absence* of progressive muscle atrophy and weakness, and multi-systemic involvement. The latter include the so-called *Muscular Channelopathies*, due to mutations in genes that code for proteins in the channels of sodium, chlorine, calcium, and potassium, some of which may be responsible for both myotonic and periodic paralysis.

Myotonia congenita is the most common muscle channelopathy. First described by Thomsen in 1876 as an autosomal dominant disease ([@B4]), a monograph on the pathology was published in 1907 by Sergio Pansini, a medical doctor at the University of Naples. The recessive form was described by PE Becker in 1963 ([@B5]). Their prevalence is estimated in 1: 100,000 live births, with onset in both childhood and adulthood ([@B2]). Depending on whether the mutation is present on both alleles or only on one of them, the clinical pictures of Becker\'s myotonia (BM, AR), or Thomsen myotonia (TM, AD), are observed. Both diseases are characterized by muscle stiffness, warm-up or heating (movement improves with repetition), trigger events (cold, stress, and exercise). Pregnancy and menstruation can worsen the symptoms. Usually patients with Becker\'s myotonia present a more severe clinical picture ([@B1]).

Myotonia congenita is due to mutations in the *CLCN1* gene (ClC-1 chlorine channel), located on the long arm of chromosome 7, in position 7q34. *CLCN1* (OMIM \# 118425) consists of 23 exons and has a transcript of 3,093 nucleotides. ClC-1 protein, consisting of 988 amino acids, represents the main voltage-dependent chloride channel in skeletal muscle cells and stabilizes the resting potential of the membrane ([@B6]). When the Cl^−^ ion conductance falls below 40%, an accumulation of K^+^ ions in the T tubules occurs, with consequent depolarization of the cell membrane and appearance of myotonia ([@B7]). More than 275 variants, causative of myotonia congenita, have been identified; about 95% of them are point mutations, while 1--5% deletions or duplications ([@B8]). Most of these mutations cause Becker myotonia, while only about 20 pathogenetic variants have so far been associated with Thomsen myotonia. At least 12 mutations can cause both pathologies for different pathogenetic mechanisms, as variants with dominant-negative effect, reduced penetrance, incomplete dominance, aplotypic background, differences in helix expression or, more simply, inability of current techniques to identify the second pathogenic variant ([@B2]). In a simplified way, mutations located at the fast gates level are recessive phenotype mutations, whereas mutations located at the slow gates level are dominant phenotype mutations ([@B9]). Recessive mutations may affect the structure of the ClC-1 protein, alter its transport, or disable the formation of dimers ([@B10], [@B11]); on the contrary dominant mutations have a dominant negative effect on dimerization ([@B10]). The diagnosis is based on clinical data, serum creatine kinase (CK) levels, usually normal or only slightly increased between 3 and 4 times the upper reference limit, presence of myotonic discharges on the EMG, and genetic analysis.

The current therapy is based on the use of drugs such as Mexiletine ([@B12]), Phenytoin, Carbamazepine and Acetazolamide ([@B13], [@B14]). However, studies in progress are evaluating new-generation molecules ([@B13], [@B15]), and "gating" or "traffic" corrector drugs through the so-called *pharmacological chaperones* ([@B16], [@B17]). We report genetic and clinical data concerning 19 patients−13 familial and 6 isolated cases---all but one originating from the Campania Region, in southern Italy.

Methods {#s2}
=======

Clinical Diagnosis
------------------

We investigated 19 patients−13 of them from 7 families---with clinically defined Myotonia congenita. All patients were referred to our clinics due to variable increases of creatine kinase (CK) or grades of muscle stiffness. At the time of the first examination, information about family history, age of onset of symptoms, current therapy was collected. All patients underwent skeletal muscle and cardiological evaluation, spirometry, routine hematochemistry, and muscle enzymes. EMG was available in 6/19 patients.

Genetic Diagnosis
-----------------

Genomic DNA was extracted from peripheral blood, collected in EDTA-containing tubes, by standard procedures. Written informed consent for DNA storage and use for genetic analysis and research purposes was obtained from all patients (parents or tutors for patients under age) and relatives, as required by the Ethical Committee of the University of Campania "Luigi Vanvitelli" in accordance with the Declaration of Helsinki. The genetic analysis was performed at the C.S.S.

Mendel Institute of Rome, Italy, through the direct sequencing of *CLCN1* gene and Sanger sequencing. The evaluation of the pathogenic variants was made through the ANNOVAR and Alamut® Software Suite (Interactive Biosoftware). Variants not described in the literature were analyzed by using dedicated softwares, such as Mutation tester, Polyphen2, Provean, M-CAP.

Results {#s3}
=======

Clinical Diagnosis
------------------

Clinical data for MC patients are shown in [Table 1](#T1){ref-type="table"}. Out of 19 patients, 13 are familial with more than one individual affected, while six are isolated cases. Of the latter, one (N17) exhibits a *de novo* mutation not found in her parents. The other five patients (N14-N16, N18-N19) show homozygous or compound heterozygous mutations, whose inheritance was confirmed in their parents.

###### 

Clinical data of MC patients.

  **Patient ID**   **Current age in Y**   **Gender**   **Age of onset in years**   **Transient weakness**   **Muscle pain/stiffness**   **Hypertrophy**   **Cold effect**   **Warm Up phenomenon**   **EMG myotonic**   **Clinical course**   **Phenotype**   **Therapy**
  ---------------- ---------------------- ------------ --------------------------- ------------------------ --------------------------- ----------------- ----------------- ------------------------ ------------------ --------------------- --------------- -------------------------
  N1               69                     M            6                           Yes                      No                          Yes               Worse             Yes                      Yes                Stable                Thomsen         None
  N2               42                     F            13                          No                       No                          No                Worse             Yes                      Yes                Stable                Thomsen         None\\Mex not effective
  N3               25                     F            6                           Yes                      No                          Yes               Worse             Yes                      Yes                Worse                 Becker          Mex, effective
  N4               28                     M            9                           Yes                      No                          Yes               Worse             Yes                      Yes                Worse                 Becker          Mex, effective
  N5               78                     F            20                          No                       Yes                         No                No                Yes                      Yes                Stable                Thomsen         Mex, effective
  N6               36                     M            20                          No                       Yes                         No                No                Yes                      Yes                Stable                Thomsen         Mex, effective
  N7               24                     M            4                           Yes                      No                          Yes               Worse             Yes                                         Stable                Becker          Mex, effective
  N8               30                     F            5                           Yes                      No                          Yes               Worse             Yes                                         Stable                Becker          Mex, effective
  N9               19                     F            asymptomatic                                                                                                                                                                           Becker          None
  N10              17                     M            2                           No                       No                          Yes               Worse             Yes                      Yes                Stable                Becker          Mex, effective
  N11              70                     M            asymptomatic                                                                                                                                                                           Thomsen         None
  N12              47                     M            6                           Yes                      Yes                         Yes               Worse             Yes                                         Stable                Thomsen         None
  N13              27                     M            15                          Yes                      No                          Yes               Worse             Yes                                         Stable                Becker          Mex, effective
  N14              53                     M            14                          Yes                      No                          Yes               No                Yes                                         Worse                 Becker          Mex, effective
  N15              32                     M            12                          Yes                      No                          Yes               Worse             Yes                                         Stable                Becker          Mex, effective
  N16              33                     F            7                           Yes                      No                          Yes               No                Yes                                         Worse                 Becker          Mex, effective
  N17              39                     F            10                          No                       No                          Yes               Worse             Yes                                         Stable                Thomsen         None
  N18              17                     F            5                           No                       Yes                         Yes               No                Yes                                         Worse                 Becker          None
  N19              42                     F            4                           Yes                      Yes                         Yes               Worse             Yes                                         Stable                Becker          None

Twelve patients (63.2%) present Becker type myotonia and seven (36.8%) Thomsen type. Sex ratio M:F in Becker type is 6:6, while in Thomsen myotonia 4:3. The age of onset of the disease ranged from 2 to 15 years in Patients with BM, and from 4 to 20 years in patients with TM. Two patients, one with Thomsen type (N11) and the other with Becker type (N9) are asymptomatic, while their relatives present the typical symptoms of the disease. The warm up phenomenon was present in 100% of patients; transient weakness, referred by 63.1% of all patients, predominates in BM patients (75%) compared with TM patients (26.3%). Muscle pain was present in 42.8% of patients with TM, but in only 16.6% of BM patients. Muscle hypertrophy and cold effect predominates in BM patients (75%) compared to TM patients (50%). The warm up phenomenon is a constant feature in both TM and BM. EMG, available in six patients---three TM and three BM---showed the typical myotonic discharges.

Muscle biopsy---performed on 5/19 patients, two Thomsen and three Becker---showed a normal histological picture in 2, aspecific alterations in 2 and absence of 2B fibers in 1 patient.

Genetic Analysis
----------------

[Figure 1](#F1){ref-type="fig"} and [Table 2](#T2){ref-type="table"} shows the mutations identified in our patients. Out of 18 identified mutations, 14 are located in the coding part of the gene (exons 1, 3, 4, 5, 7, 8, 13, 15, 21, 22) and 4 in the intron part (introns 1, 2, 10, 18). All the exonic mutations but two are missense mutations. Some of them such as p. His29Pro, p.Phe167Leu, p.Val273Met, and p.Val851Met, occur with a relative higher frequency.

![CLCN1 Mutations identified in the studied cohort.](fneur-11-00063-g0001){#F1}

###### 

Genetic data of MC patients.

  **Patient ID**   **Current age in years**   **Gender**   **Inheritance**   **Relationship**                 **Exon/Intron position**   **DNA change**                                       **Protein**
  ---------------- -------------------------- ------------ ----------------- -------------------------------- -------------------------- ---------------------------------------------------- -------------------------------------------
  N1               69                         M            AD                Father of N2                     ex 1 + ex 22/int 10        c\. 86A \> C + c.2551G \> A in cis/c.1167-10T \> C   p\. His29Pro + p. Val851Met in cis /?
  N2               42                         F            AD                Daughter of N1                   ex 1 + ex 22/int 10        c\. 86A \> C + c.2551G \> A in cis/c.1167-10T \> C   p\. His29Pro + p. Val851Met in cis /?
  N3               25                         F            AR                Niece of N1 and sister of N4     ex 4/int. 10               c.501C \> G/c. 1167-10T \> C                         p.Phe167Leu/?
  N4               28                         M            AR                Nephew of N1 and brother of N3   ex 4/int. 10               c.501C \> G/c. 1167-10T \> C                         p.Phe167Leu/?
  N5               78                         F            AD                Mother of N6                     ex 7/ex 8 + int 18         c\. 817G \> A/c.899G \> A + c.2284+5C \> T in cis    p.Val273Met/p.Arg300Gln + ?
  N6               36                         M            AD                Son of N5                        ex 7                       c.817G \> A heterozygous                             p.Val273Met
  N7               24                         M            AR                Brother of N8                    ex 15                      c.1785G \> A homozygous                              p.Trp595[^\*^](#TN1){ref-type="table-fn"}
  N8               30                         F            AR                Sister of N7                     ex 15                      c.1785G \> A homozygous                              p.Trp595[^\*^](#TN1){ref-type="table-fn"}
  N9               19                         F            AR                Sister of N10                    int 2/ex 5                 c.302-1G \> A/c.568-569GG \> TC                      ?/p. Gly190Ser
  N10              17                         M            AR                Brother of N9                    int 2/ex 5                 c.302-1G \> A/c.568-569GG \> TC                      ?/p. Gly190Ser
  N11              70                         M            AD                Father of N12                    ex 3 + ex 4                c.313C \> T + c.501C \> G in cis                     p.Arg105Cys + p.Phe167Leu in cis
  N12              47                         M            AD                Son of N11                       ex 3 + ex 4                c.313C \> T + c.501C \> G in cis                     p.Arg105Cys + p.Phe167Leu in cis
  N13              27                         M            AR                2 siblings affected              int 2/ex 7                 c.302-1G \> A/c.826G \> A                            ?/p.Gly276Ser
  N14              53                         M            AR                                                 ex 7                       c.817G \> A homozygous                               p.Val273Met
  N15              32                         M            AR                                                 int 1/ex 21                c.180+3A \> T/c.2495C \> T                           p.THr832Ile
  N16              33                         F            AR                                                 ex 13                      c.1403T \> C homozygous                              p\. Phe468Ser
  N17              39                         F            AD                *De novo* mutation               ex 22                      c.2551G \> A heterozygous                            p\. Val851Met
  N18              17                         F            AR                                                 ex 1 /ex 7                 c.86A \> C/c.817G \> A                               p.His29Pro/p.Val273Met
  N19              42                         F            AR                                                 ex 21                      c.2423C \> T homozygous                              p.Gln812[^\*^](#TN1){ref-type="table-fn"}

*indicates stop codon point mutation*.

About 70% of mutations are inherited with an AR pattern, the mutation p.Val851Met with an AD pattern, two---p.His29Pro and p.Val273Met -- with both mechanisms.

Patients sharing the protein variation p.Gly190Ser have a more severe phenotype than patients with the mutations p. Phe167Leu or Arg105Cys.

Three novel mutations were identified, never described in the literature p. Gly276Ser, Phe486Ser, and p.Gln812^\*^, associated with Becker phenotype, two in homozygosis and one in compound heterozygosity. The neuromyological examination of these three patients revealed in the first case (mutation p. Gly276Ser) a slowly progressive Becker phenotype with onset at the age of 16, associated with muscle stiffness, transient weakness cold-aggravated, hand and jaw myotonia; in the second patient (mutation p.Phe486Ser), the onset was earlier, at the age of 7, and the clinical course more severe; in the third patient (mutation p. Gln812^\*^), the onset was in childhood, but the disease\'s course was mild and, at the current age of 42, the patient reports to be stable.

In three unrelated families (N1; N5; N11) two *CLCN1* mutations, inherited in cis on the same allele were identified, in particular *c.86A* \> *C* + *c. 2551G* \> *A*, (patients N1-N2), *c.313C* \> *T* + *501C* \> *G* (patients N11-N12), and *c.899G* \> *A* + *c.2284*+*5C* \> *T* (patient N5).

The family N1--N4 (see family tree in [Figure 2](#F2){ref-type="fig"}) deserves particular comment. The father (N1 in the tables) and one of the three daughters (N2 in the tables) show the cis mutation *c.86A* \> *C* + *c. 2551G* \> *A* (pathogenetic) on one allele, and the mutation c. *1167-10T*\> *C* on the other allele. The other two daughters inherited the mutation *c. 1167-10T* \> *C* and are clinically unaffected. However, one of the two unaffected daughters had---quite unexpectedly---two children (individuals N3 and N4 in the tables) showing the characteristic symptoms of myotonia since their childhood. The genetic analysis in this part of the family revealed that her husband---unaffected---was a carrier of the mutation *c.501C* \> *G* in the CLCN1gene, found in combination with *c. 1167-10T* \> *C* in N3 and N4. Therefore, the combination of the mutations *c. 1167-10T* \> *C* and *c.501C* \> *G* may explain the affected phenotype observed in N3 and N4 (see the family tree). In fact, the mutation *c.501C* \> *G* has been already described as affecting or probably affecting function in both compound heterozygosity and in homozygosity ([@B14]).

![Family tree of individuals N1--N4.](fneur-11-00063-g0002){#F2}

Four mutations found in our cohort of patients, in particular p. Arg105Cys, p.Gly190Ser, p.Thr832Ile, and p.Val851Met were electrophysiologically studied by the group of prof. F. Desaphy and their characteristics published by Altamura et al. ([@B6]).

An intra-familial phenotypic variability was observed in two families (patients N9-N10 and N11-N12), one with Thomsen and the other with Becker myotonia. An incomplete penetrance was hypothesized in the Thomsen family, as the father at the age of 70 is still asymptomatic while the son presents symptoms since the age of 6.

Eleven patients were on mexiletine, with an improvement of symptoms; in one patient the drug was ineffective; seven refused therapy. An improvement in muscle symptoms was reported by two patients undergoing steroid therapy for intercurrent diseases.

Discussion {#s4}
==========

Mutations in *CLCN1* are widely distributed along the entire gene sequence ([@B12]). Unlike the report by Brugnoni et al. ([@B14]), who described in a cohort of 106 Italian patients a higher frequency of mutations in exons 4 and 5 of the *CLCN1* gene, mutations in these exons were only seen in 3 of our families.

The mutation p. Gly190Ser, found in both Thomsen and Becker phenotypes, causes a more severe clinical presentation in the latter, compared with mutations p. Phe167Leu or p. Arg105Cys, as demonstrated through the electrophysiological studies by Desaphy et al. ([@B18]) and Egushi et al. ([@B14]).

The neuromyological examination of the three patients carrying the novel mutations p.Gly276Ser, p.Phe468Ser, and p. Gln812^\*^ revealed a different clinical presentation, with a more severe course of the disease associated to the mutation p. Phe486Ser. We report the first case of documented concomitant occurrence of Thomsen and Becker clinical pictures in the same family.

In conclusion, our data, describe a set of *CLCN1* mutations in the population of Southern Italy different from those previously indicated ([@B19]--[@B21]) in the Italian cohort of MC patients. Furthermore, they report three novel mutations that widen the spectrum of mutations characterizing the clinical picture of these patients.
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